Find clinical trials for Melanoma in Baltimore, MD
CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Related conditions:
Melanoma trials near Baltimore, MD, USA:
This is a Phase 3, randomized, multi-center, open-label study of neoadjuvant darovasertib in subjects with primary non-metastatic uveal melanoma...
Phase 3
Baltimore, Maryland, United States and 59 other locations
In this phase II advanced melanoma study, all patients will receive treatment with nivolumab/ipilimumab plus cabozantinib for a 12 week indu...
Phase 2
Baltimore, Maryland, United States and 2 other locations
(PK) similarity and efficacy, safety, and immunogenicity of ABP 206 compared with OPDIVO® (nivolumab) in subjects with resected advanced melanoma...
Phase 3
Baltimore, Maryland, United States and 110 other locations
alone in participants with untreated, unresectable or metastatic melanoma. Participants randomized to the pembrolizumab monotherapy arm who ...
Phase 3
Bethesda, Maryland, United States and 71 other locations
cell death protein-1 (PD-1) inhibitor, in patients with metastatic melanomas or advanced solid tumors. Our hypothesis is that restoration of...
Phase 1, Phase 2
Washington, District of Columbia, United States and 20 other locations
The study is focused on patients with a type of skin cancer known as melanoma. The aim of the study is to see how safe and effective the com...
Phase 3
Columbia, Maryland, United States and 100 other locations
of ceralasertib, when administered as monotherapy and in combination with durvalumab in participants with unresectable or advanced melanoma ...
Phase 2
Lutherville-Timonium, Maryland, United States and 65 other locations
assess the efficacy, safety, and immunogenicity of ABP 206 compared with Nivolumab in Subjects with Treatment-Naïve Unresectable or Metastatic Melanoma...
Phase 3
Baltimore, Maryland, United States and 185 other locations
and pharmacokinetic profiles of botensilimab as monotherapy and in combination with balstilimab in participants with advanced cutaneous melanoma...
Phase 2
Washington, District of Columbia, United States and 50 other locations
patients with unresectable Stage III or IV melanoma. The contributions of BNT111 and cemiplimab will be delineated in single agent...
Phase 2
Fairfax, Virginia, United States and 48 other locations
Clinical trials
Research sites
Resources
Legal